Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications

Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications

Chimeric Antigen Receptor T (CAR-T) cell therapy has dramatically changed prognosis and treatment of relapsed and refractory hematologic malignancies. Currently the 6 FDA approved products target various surface antigens. While CAR-T therapy achieves good response, life-threatening toxicities have b...

Full description

Bibliographic Details
Main Authors: Simon R. Mucha, Prabalini Rajendram
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Current Oncology
Subjects:
chimeric antigen receptor T-cell therapy (CAR-T)
adoptive immune cell therapy
cytokine release syndrome
late complications
cytopenias
hypogammaglobulinemia
Online Access:https://www.mdpi.com/1718-7729/30/5/378

Internet

https://www.mdpi.com/1718-7729/30/5/378

Similar Items